About this material
The Cordyceps category in the MushroomReferences.com catalog holds 41 publications. Most are preclinical (in vitro, animal), but unlike reishi, cordyceps has several reproducible clinical results in humans. This review collects the clinical directions with sample sizes and limitations noted. The species cards are in the catalog.
What cordyceps is
Cordyceps is a genus of ascomycete fungi parasitizing insects and other fungi. The best known is Cordyceps sinensis (Chinese "sordony tibet") — a wild species collected in the highlands of Tibet and Nepal. For clinical and commercial purposes, cultivated Cordyceps militaris or Paecilomyces hepiali mycelium (Cs-4) grown on grain substrate is used more often. This distinction matters: results obtained with C. sinensis do not automatically transfer to C. militaris and vice versa.
Main active substances
- Cordycepin (3'-deoxyadenosine) — a nucleoside with immunomodulating and anti-inflammatory action. Found mainly in C. militaris.
- β-(1→3)/(1→6)-glucans — the fraction common to wood-decay fungi.
- Adenosine, polyamines, mannitol — low-molecular-weight components associated with cardiovascular and energy-metabolism effects.
Cordycepin content varies greatly across commercial products: C. militaris contains more than C. sinensis and mycelium-on-grain.
Clinical data: what exists
Physical performance and endurance
Several RCTs (n = 20–60) in healthy volunteers and elderly people showed that cordyceps extracts (2–12 weeks):
- increased time to exhaustion during aerobic exercise;
- raised peak oxygen uptake (VO₂max) by 5–10%;
- improved subjective recovery measures after exertion.
This is one of the most reproducible directions. Proposed mechanisms include increased ATP production, better oxygen utilization and antioxidant action.
Kidney function
In several small clinical studies (mostly Chinese) in patients with chronic kidney disease (CKD), Cordyceps sinensis / Cs-4:
- slowed CKD progression (by creatinine and GFR);
- reduced proteinuria;
- improved subjective quality-of-life measures.
Most of these are open-label studies; placebo-controlled RCTs are few. Large international multicentre trials have not been conducted.
Immunomodulation
Human clinical data here are limited. In laboratory and animal models cordyceps enhanced NK-cell activity and stimulated lymphocyte proliferation, but in human clinical work the effect size is modest and not consistently reproduced. The general mechanisms are covered in Beta-glucans and immunity and the Mushrooms and immunity topic.
Anemia (athletes, elderly)
Several small studies showed Cordyceps militaris improved red-blood measures (hemoglobin, hematocrit) in athletes with exercise-induced anemia and in the elderly. These data need confirmation in larger RCTs.
Lipid profile and glycemia
Some clinical work reports small reductions in LDL and triglycerides and modest improvement in insulin sensitivity. The effect is modest and not yet confirmed in large RCTs.
Where the evidence is weak
- Antitumour action. No convincing human clinical data. Preclinical work is interesting but extrapolation to patients is invalid.
- Antiviral activity. Laboratory effects exist; human RCTs for specific viral infections are lacking.
- Hepato- and neuroprotection. Mostly preclinical data.
- Long-term safety. In short-term studies (up to 12 weeks) side effects are rare (occasionally mild GI discomfort). Long-term RCTs are few.
Commercial product quality
The same problem as with other mushroom supplements (details in Mushroom supplements in Italy):
- substitution of expensive C. sinensis with cheap C. militaris or mycelium-on-grain;
- cordycepin and β-glucan content below the declared levels;
- in cheap products the bulk of the mass is the grain substrate the mycelium was grown on.
Practically, this means the clinical cordycepin doses (1–3 mg/day) are often unreachable in a random commercial supplement.
What is important to keep in mind
- Do not confuse the species. Results with C. sinensis ≠ results with C. militaris ≠ results with Cs-4 mycelium. Their active-compound profiles differ.
- Cordyceps is a dietary supplement. Not registered as a medicine in the EU or Russia.
- Interactions. Cordyceps may potentiate hypoglycemic and antihypertensive drugs and anticoagulants — a documented effect, not a formality.
- Standardization is critical. Products cannot be compared without the species, the part used (fruiting body / mycelium) and cordycepin content stated.
- Not a substitute for CKD treatment. For patients with kidney disease, any decisions belong with the treating nephrologist.
Related materials
- Catalog: Mushroom catalog
- Mechanisms: Beta-glucans and immunity, topic Mushrooms and immunity
- Use: Mushroom supplements in integrative oncology
- Quality: Mushroom supplements in Italy
- Other wood-decay fungi: Reishi, Chaga, Lion's mane, Agarikon
- Sources